This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2005.07.062v1 46/11/1986    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by Kaul, S. Articles by Weintraub, W. S. Search for Related Content PubMed PubMed Citation Articles by Kaul, S. Articles by Weintraub, W. S.

STATE-OF-THE-ART PAPER

Trials and Tribulations of Non-Inferiority

The Ximelagatran Experience

Sanjay Kaul, MD^_*,_*, George A. Diamond, MD, FACC^_* and William S. Weintraub, MD, FACC

^_* Division of Cardiology, Cedars-Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California
Emory Center for Outcomes Research, Emory University, Atlanta, Georgia

Manuscript received May 21, 2005; revised manuscript received July 6, 2005, accepted July 11, 2005.

^_* Reprint requests and correspondence: Dr. Sanjay Kaul, Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048. (Email: kaul{at}cshs.org).

Ximelagatran is a novel oral direct thrombin inhibitor that offers a number of advantages over the standard treatment, warfarin, in patients with atrial fibrillation. Two large clinical trials, one open-label (Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation [SPORTIF] III), one double-blind (SPORTIF V), have compared the efficacy and safety of fixed-dose ximelagatran without anticoagulation monitoring with dose-adjusted warfarin using a non-inferiority design. On the basis of the results, the investigators concluded that ximelagatran was just as effective as warfarin in preventing stroke or systemic embolism (the primary end point), because the pre-specified non-inferiority criterion was met. Reanalysis of the data with rather conservative interpretive criteria, however, revealed a number of deficiencies: 1) an unreasonably generous margin that was potentially biased toward non-inferiority, given the low baseline event rate of warfarin; 2) the inappropriateness of the analytical method used to estimate the non-inferiority margin; 3) a lack of confidence that ximelagatran retains at least 50% of warfarin’s effect (a prerequisite to the establishment of non-inferiority); 4) significant heterogeneity in the magnitude of efficacy observed in the two trials; and 5) safety concerns regarding increased liver toxicity with ximelagatran without a significant offsetting advantage in major bleeding. This imbalance in the benefit-risk profile materially undermines the investigators’ claim of non-inferiority of ximelagatran and led the Food and Drug Administration to reject the sponsor’s application for ximelagatran. Despite published conclusions to the contrary, we conclude that ximelagatran has not been shown to be non-inferior to warfarin. Such determinations of non-inferiority are highly dependent on the underlying assumptions, and graphical sensitivity analyses make this dependence explicit.

Abbreviations and Acronyms   AF = atrial fibrillation   CI = confidence interval   FDA = Food and Drug Administration   SPORTIF = Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation

This article has been cited by other articles:

				B. K. Nallamothu, R. A. Hayward, and E. R. Bates Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies Circulation, September 16, 2008; 118(12): 1294 - 1303. [Full Text] [PDF]

				D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]

				S. Kaul, G. A. Diamond, and W. S. Weintraub Reply J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1059 - 1059. [Full Text] [PDF]

				G. W. Albers, H.-C. Diener, L. Frison, M. Grind, J. Horrow, M. Nevinson, S. B. Olsson, S. Partridge, P. Petersen, A. Vahanian, et al. Trials and Tribulations of Noninferiority: The Ximelagatran Experience J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1058 - 1058. [Full Text] [PDF]

				S. Kaul and G. A. Diamond Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials Ann Intern Med, July 4, 2006; 145(1): 62 - 69. [Abstract] [Full Text] [PDF]

				P. C. Gotzsche Lessons From and Cautions About Noninferiority and Equivalence Randomized Trials JAMA, March 8, 2006; 295(10): 1172 - 1174. [Full Text] [PDF]